Albin N - Search Results

1

How to strengthen the presence of patients in health technology assessments conducted by the health authorities.

Mamzer MF, Dubois S, Saout C; participants of Round Table «Topical Subject» of Giens XXXIII; Albin N, Béhier JM, Buisson A, Diebolt V, Delaitre O, Duguet C, Fagon JY, Gaillard S, Le Jeunne C, Mazars R, Micallef J, Nabarette H, Piazza L, Raynaud C, Varoqueaux N. Mamzer MF, et al. Among authors: albin n. Therapie. 2018 Feb;73(1):95-105. doi: 10.1016/j.therap.2017.11.004. Epub 2017 Dec 21. Therapie. 2018. PMID: 29478707 French.

2

Accès précoce aux produits de santé en France : des avancées majeures du CSIS (Conseil stratégique des industries de santé) à concrétiser (modalités, réglementations, financements).

Albin N, Chassagnol F, Bergmann JF; Les participants à la table ronde « Aspects organisationnels et réglementaires » des Ateliers de Giens XXXIV; avec la collaboration de. Albin N, et al. Therapie. 2019 Feb;74(1):87-101. doi: 10.1016/j.therap.2018.11.009. Epub 2018 Dec 6. Therapie. 2019. PMID: 30612729 French. No abstract available.

3

Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding).

Albin N, Chassagnol F, Bergmann JF; participants of Giens XXXIV Round Table “Organisational and regulatory aspects”; with collaboration. Albin N, et al. Therapie. 2019 Feb;74(1):103-117. doi: 10.1016/j.therap.2018.12.002. Epub 2018 Dec 13. Therapie. 2019. PMID: 30745156

4

Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program.

Pham FY, Jacquet E, Monard A, Brunel L, Blay JY, Albin N. Pham FY, et al. Among authors: albin n. Ann Oncol. 2022 May;33(5):561-563. doi: 10.1016/j.annonc.2022.02.002. Epub 2022 Feb 14. Ann Oncol. 2022. PMID: 35176459 Free article. No abstract available.

5

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.

Jacquet E, Kerouani-Lafaye G, Grude F, Goncalves S, Lorence A, Turcry F, Brunel L, Belgodere L, Monard A, Guyader G, Boudali L, Albin N. Jacquet E, et al. Among authors: albin n. Eur J Cancer. 2021 May;149:82-90. doi: 10.1016/j.ejca.2021.03.008. Epub 2021 Apr 7. Eur J Cancer. 2021. PMID: 33838392 Free article.

6

[Administrative delays of temporary recommendation for use: Impact on access to innovation in melanoma].

Auger C, Guillot B, Monard A, Albin N. Auger C, et al. Among authors: albin n. Bull Cancer. 2022 Jan;109(1):28-37. doi: 10.1016/j.bulcan.2021.11.007. Epub 2021 Dec 28. Bull Cancer. 2022. PMID: 34972538 Free article. French.

7

[Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].

Albin N, Mc Leer A, Sakhri L. Albin N, et al. Bull Cancer. 2018 Apr;105(4):375-396. doi: 10.1016/j.bulcan.2018.01.009. Epub 2018 Mar 1. Bull Cancer. 2018. PMID: 29501208 Review. French.

8

Access to innovation through the national early access program and clinical trials for patients with malignant melanoma.

Christen C, Belgodère L, Guillot B, Jumeau C, Lorence A, Kerouani-Lafaye G, Brunel L, Turcry F, Monard A, Grudé F, Guyader G, Boudali L, Albin N. Christen C, et al. Among authors: albin n. Cancer. 2021 Jul 1;127(13):2262-2270. doi: 10.1002/cncr.33492. Epub 2021 Mar 25. Cancer. 2021. PMID: 33764524 Free PMC article.

9

Response to the letter: Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.

Jacquet E, Monard A, Albin N. Jacquet E, et al. Among authors: albin n. Eur J Cancer. 2021 Oct;156:222-224. doi: 10.1016/j.ejca.2021.07.003. Epub 2021 Aug 18. Eur J Cancer. 2021. PMID: 34419329 No abstract available.

10

Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.

Pham FY, Jacquet E, Taleb A, Monard A, Kerouani-Lafaye G, Turcry F, Brunel L, Grudé F, Yoldjian I, Sainte-Marie I, Boudali L, Blay JY, Albin N. Pham FY, et al. Among authors: albin n. Int J Cancer. 2022 Oct 15;151(8):1345-1354. doi: 10.1002/ijc.34129. Epub 2022 Jul 7. Int J Cancer. 2022. PMID: 35603979 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page